Bonviva provides more treatment opportunity in patients with osteoporosis

Published: 2008-07-07 06:56:00

Updated: 2008-07-07 06:56:00

Once-monthly Bonviva (ibandronate) has comparable efficacy to other bisphosphonates in a diverse population of patients in clinical settings and clinicians will have a greater awareness of patient compliance with Bonviva therapy, according to Professor Jonathan D. Adachi, Depart of Medicine of Mc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK